AngioDynamics (ANGO)
(Real Time Quote from BATS)
$7.56 USD
-0.21 (-2.70%)
Updated Aug 5, 2024 02:40 PM ET
1-Strong Buy of 5 1
B Value B Growth D Momentum B VGM
Price, Consensus and EPS Surprise
ANGO 7.56 -0.21(-2.70%)
Will ANGO be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANGO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ANGO
Should You Buy AngioDynamics (ANGO) After Golden Cross?
Boston Scientific (BSX) Rides on Global Growth, Buyouts
ANGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 74.25% Upside in AngioDynamics (ANGO): Here's What You Should Know
New Strong Buy Stocks for July 29th
AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down
Other News for ANGO
AngioDynamics to Participate in Upcoming Investor Conferences
Reaffirmed Buy Rating on AngioDynamics: A Strategic Assessment of Growth and Valuation Prospects
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Argenx Se (ARGX) and AngioDynamics (ANGO)
AngioDynamics price target lowered by $5 at Canaccord, here's why
AngioDynamics: Lumpy Progress Is Still Progress